Skip to main content
Everest Medicines Limited logo

Everest Medicines Limited — Investor Relations & Filings

Ticker · 1952 LEI · 3003005FQADBCG83AX84 HKEX Manufacturing
Open in API
Filings indexed 313 across all filing types
Latest filing 2026-04-27 M&A Activity
Country KY Cayman Islands
Listing HKEX 1952

About Everest Medicines Limited

http://www.everestmedicines.com

Everest Medicines Limited is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and commercializing transformative pharmaceutical products and vaccines. The company focuses on licensing-in and advancing therapies to address critical unmet medical needs, primarily targeting patients across Greater China and other Asian Pacific markets. Its commercialized portfolio includes products such as XERAVA (eravacycline), approved for treating complicated intra-abdominal infections (cIAI).

Recent filings

Filing Released Lang Actions
SUPPLEMENTAL ANNOUNCEMENT DISCLOSEABLE TRANSACTION IN RELATION TO THE ASSET PURCHASE AGREEMENT
M&A Activity Classification · 1% confidence The document is a supplemental announcement providing additional details on a previously disclosed Asset Purchase Agreement and related transactions. It describes the assignment of contracts, conditions precedent, and background of the seller, which is characteristic of an M&A transaction announcement rather than a financial report or earnings release. It is not a mere notice of publication nor a board change, dividend, or regulatory fallback. Therefore, it falls under M&A Activity (Code: TAR).
2026-04-27 English
Reminder letter and Reply Form to Non-Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications
Regulatory Filings
2026-04-23 English
2025 Environmental, Social and Governance Report
Regulatory Filings
2026-04-23 English
Reminder letter and Reply Form to Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications
Regulatory Filings Classification · 1% confidence The document is a reminder letter to registered shareholders about the arrangement for electronic dissemination of corporate communications and includes a reply form for shareholders to provide or update their email addresses. It is not an actual financial report, proxy statement for a specific meeting, or details of votes or dividends. It does not announce publication of a specific report (RPA), nor does it fit any specialized category (e.g., 10-K, IR, ER, PSI). It is a general shareholder communication regarding administrative arrangements and therefore falls into the fallback category of general regulatory announcements. Accordingly, it should be classified as a Regulatory Filing (RNS).
2026-04-23 English
2025 Annual Report
Regulatory Filings
2026-04-23 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026
Share Issue/Capital Change Classification · 1% confidence The document is a mandatory monthly return (Form FF301) filed under the Hong Kong Exchange Listing Rules specifying movements in authorised/registered share capital, issued shares, treasury shares, share option exercises, and related capital changes. It is not an earnings release, annual report, AGM material, or management discussion, nor solely a share buyback notice. It details share issues and overall capital changes and therefore falls under “Share Issue/Capital Change (SHA).”
2026-04-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.